Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)-Reference-Cited by-同舟云学术

Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)

Published:2017-01 Issue:1 Volume:119 Page:40-46
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Gaudet Daniel,Watts Gerald F.,Robinson Jennifer G.,Minini Pascal,Sasiela William J.,Edelberg Jay,Louie Michael J.,Raal Frederick J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference26 articles.

1. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial;Bays;J Clin Endocrinol Metab,2015

2. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial;Cannon;Eur Heart J,2015

3. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial;Farnier;Atherosclerosis,2016

4. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia;Kastelein;Eur Heart J,2015

5. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dL or higher;Ginsberg;Cardiovasc Drugs Ther,2016

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9;European Journal of Clinical Investigation;2024-06-26

2. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome;Canadian Journal of Cardiology;2023-10

3. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives;International Journal of Environmental Research and Public Health;2023-09-06

4. Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor;Pharmacological Research;2023-08

5. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-07-26